Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several European registries have since validated the ESC/ERS risk status model; however, it is unknown if the ESC/ERS tool predicts clinical worsening or hospitalizations.(288)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [288]
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationSelexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationBenza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. J., Badesch, D. B., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-0676 · Cited by 557
Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., Nisell, M., Söderberg, S., Wikström, G., & Rådegran, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx257 · Cited by 540
Hoeper, M. M., Huscher, D., Ghofrani, H. A., Delcroix, M., Distler, O., Schweiger, C., Grunig, E., Staehler, G., Rosenkranz, S., Halank, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.026 · Cited by 466
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Cited by
Items 301–400 of 739
miR-34a targets PAI-1 to regulate urinary microalbumin and renal function in hypertensive mice
Liu, R., Yang, L., & Wei, Q. (2020) · European journal of medical research · doi:10.1186/s40001-020-00404-7 · Cited by 12
The Role of Exercise Testing in Pulmonary Vascular Disease
Systrom, D., Warren, A., & Naeije, R. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.11.003 · Cited by 12
Park, D., Fuge, J., Meltendorf, T., Kahl, K. G., Richter, M. J., Gall, H. J., Ghofrani, H. A., Kamp, J. C., Hoeper, M. M., & Olsson, K. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.668647 · Cited by 12
Self-citationChen, Y., Luo, J., Chen, J., Kotlyar, E., Li, Z., Chen, W., & Li, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.811700 · Cited by 12
“The correspondence between the low-, intermediate-, and high-risk groups, as defined by the REVEAL 2.0 calculator, were as follows: low risk REVEAL score ≤ 6, intermediate risk REVEAL score 7 and 8, and high risk REVEAL score ≥ 9 (Hoeper et al., 2017).”
MethodInfluentialWang, Q., Qian, J., Li, M., Zhang, X., Wei, W., Zuo, X., Zhu, P., Ye, S., Zhang, W., Zheng, Y., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221112528 · Cited by 12
The potential of cystatin C as a predictive biomarker in pulmonary hypertension
Duan, A., Huang, Z., Zhao, Z., Zhao, Q., Jin, Q., Yan, L., Zhang, Y., Li, X., Zhang, S., Hu, M., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02595-1 · Cited by 12
“…version of the risk stratification scheme recommended by PH guidelines [19] was performed to categorize patients into low, intermediate or high-risk groups using the following variables: WHO-FC, 6MWD, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, RAP, cardiac index and SvO 2 [20].”
MethodCharacterization of fibroblasts from hypertrophied right ventricle of pulmonary hypertensive rats
Imoto, K., Okada, M., & Yamawaki, H. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2158-4 · Cited by 12
Zhao, Q., Chen, J., Chen, F., Ruan, H., Zhang, W., Zhou, Y., Wang, Q., Xu, X., Feng, K.-F., Jian-zhou, G., et al. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12351 · Cited by 11
Yogeswaran, A., Petermann, R., Kremer, N., Schäfer, S., Rako, Z. A., Vanderpool, R. R., Tedford, R. J., & Tello, K. (2024) · ERJ Open Research · doi:10.1183/23120541.00685-2024 · Cited by 11
“…described by gold-standard multi-beat E es / E a ratio, is an independent risk factor highlighted by multivariate Cox regression analyses adjusted for major risk factors including age, sex, pulmonary haemodynamics, brain natriuretic peptide, renal function and RV ejection fraction [12, 13].”
Baxan, N., Zhao, L., Ashek, A., Niglas, M., Wang, D., Khassafi, F., Sabrin, F., Dubois, O., Chen, C.-N., Pullamsetti, S. S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-79029-3 · Cited by 11
Huang, W., Hsieh, S., Wu, Y., Hsieh, T., Wu, Y., Li, K., Charng, M., Chen, W., Sung, S., Tsao, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202303_39(2).20230117a · Cited by 11
Heterogeneity of treatment effects by risk in pulmonary arterial hypertension
Pan, H., McClelland, R. L., Moutchia, J., Appleby, D. H., Fritz, J. S., Holmes, J. H., Minhas, J., Palevsky, H. I., Urbanowicz, R. J., Kawut, S. M., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00190-2023 · Cited by 11
Perioperative Management in Pulmonary Endarterectomy
Jenkins, D. P., Martinez, G. C., Salaunkey, K., Reddy, S. A., & Pepke‐Żaba, J. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1770123 · Cited by 11
Zhang, J., Meng, H., Yin, Y., Zhang, Y., Wen, Y., Zhang, R., & Wang, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102026 · Cited by 11
Qu, J., Li, M., Zhang, X., Zhang, M., Zuo, X., Zhu, P., Ye, S., Zhang, W. Y., Zheng, Y., Qi, W., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02522-2 · Cited by 11
“…1 PAH, such as the 2015 and 2022 European Society of Cardiology (ESC) / European Respiratory Society (ERS) guidelines [5, 6], the risk scores derived from the ESC/ERS guideline risk table [7–9] and the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) prognostic tools [10].”
BackgroundVeld, A. E. H. I. ‘., van de Veerdonk, M. C., Spruijt, O. A., Groeneveldt, J. A., Marcus, J. T., Westerhof, N., Bogaard, H. J., & Noordegraaf, A. V. (2019) · Pulmonary Circulation · doi:10.1177/2045894018824553 · Cited by 11
“The comparison between our CMR-based treatment strategy and existing risk-assessment strategies is especially relevant given the availability of several recent cohort studies demonstrating the clinical and prognostic relevance of guideline-derived risk assessment.(12,18,19) These studies have consistently shown that a…”
ResultProteomic analysis of pulmonary arterial hypertension
Qin, X., Li, T., Sun, W., Guo, X., & Fang, Q. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211047304 · Cited by 11
The use of pulmonary arterial hypertension therapies in Eisenmenger syndrome
Arvanitaki, A., & Diller, G. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2021069 · Cited by 11
“Risk scores applied in other forms of PAH, for example, the risk stratification tool proposed by the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines [52], with its abbreviated versions [53,54]; and the Registry to”
MethodRamani, G. V., Cassady, S. J., Shen, E., Broderick, M. J., Wasik, A., Sui, Q., & Nelsen, A. C. (2020) · Pulmonary Circulation · doi:10.1177/2045894020923956 · Cited by 11
“Although the validity of the 6MWD as a surrogate endpoint is often questioned, findings from European PAH registries have confirmed that 6MWD at both baseline and at follow-up is a strong clinical prognosticator.(26,27) Recent clinical trials have emphasized the importance of preventing clinical worsening and PAHrelat…”
BackgroundImaging risk in pulmonary arterial hypertension
Badagliacca, R., & Vizza, C. D. (2020) · European Respiratory Journal · doi:10.1183/13993003.02313-2020 · Cited by 11
Self-citationFarber, H. W., Chakinala, M. M., Cho, M., Frantz, R. P., Frick, A., LANCASTER, L. H., Milligan, S., Oudiz, R. J., Panjabi, S. S., Tsang, Y., et al. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12258 · Cited by 10
“com), with the scoring methodology (1 = low risk, 2 = intermediate risk, 3 = high risk) adapted from the Swedish PAH Registry.(15,16) Parameters collected over time (where available) in the TRIO CIPDR included PAH‐specific medications (including dose, route of administration, start/stop dates, and reasons for disconti…”
MethodDiagnosis and Management of Pulmonary Hypertension: New Insights
Ntiloudi, D., Kasinos, N., Kalesi, A. E., Vagenakis, G. A., Theodosis-Georgilas, A., & Rammos, S. (2024) · Diagnostics · doi:10.3390/diagnostics14182052 · Cited by 10
“…risk tools, including the Swedish Pulmonary Arterial Hypertension Registry, the Comparative, Prospective Registry of Newly Initiated Therapies for PH (COMPERA), the French PH Network Registry, and the US Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) risk equation [40–46].”
MethodMedical Treatment of Pulmonary Arterial Hypertension
Sahay, S., Humbert, M. J. C., & Sitbon, O. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1607208 · Cited by 10
Pulmonary Hypertension and Right Ventricular Failure
Huston, J., Brittain, E. L., & Robbins, I. M. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2020.01.002 · Cited by 10
Padervinskienė, L., Hoppenot, D., Krivickienė, A., Gumauskienė, B., Nedzelskienė, I., Šimkus, P., Miliauskas, S., Jankauskas, A., Basevičius, A., & Ereminienė, E. (2020) · Medicina · doi:10.3390/medicina56040167 · Cited by 10
Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
Quan, R., Yang, Y., Yang, Z., Tian, H., Li, S., Shen, J., Ji, Y., Zhang, G., Zhang, C., Wang, G., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01495-6 · Cited by 10
“In the univariable analyses, 6MWD, WHO-FC, NT-proBNP, cardiac index, RAP and mixed venous oxygen saturation (SvO2), which were included as variables in the Swedish/COMPERA risk stratification method, showed significant prognostic value for mortality [15, 16].”
MethodSelexipag for pulmonary arterial hypertension in a wide range of adult congenital heart disease
van Dissel, A. C., Post, M. C., Sieswerda, G. T., Vliegen, H. W., van Dijk, A. P. J., Mulder, B. J. M., & Bouma, B. J. (2021) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2021.100144 · Cited by 10
Bikou, O., Tharakan, S., Yamada, K. P., Kariya, T., Agüero, J., Gordon, A., Mazurek, R., Aikawa, T., Kohlbrenner, E., Fish, K. M., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.274 · Cited by 10
Cuesta, V. M. M., Meñaca, A. M., Fernandez, D. I., Mena, S. T., Alonso‐Lecue, P., Márquez, D. F., Belmonte, B. S., Ruiz, M. J. G., & Martínez, J. M. C. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12149 · Cited by 10
“Both the Swedish method and the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) use a similar strategy, whereby scores from 1 to 3 are assigned to each variable (1 = low risk; 2 = intermediate risk; 3 = high risk) and a rounded mean of these scores defines the risk g…”
MethodZhang, Y., Li, X., Jin, Q., Luo, Q., Zhao, Q., Yang, T., Zeng, Q., Yan, L., Duan, A., Huang, Z., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02232-1 · Cited by 10
“0 3-S risk score, which was consistent with the previous studies [2, 4].”
ResultLi, X., Sun, X., Huang, Y., Wang, Y., Yang, X., Wang, J., Zhang, N., Gu, L., Zhang, M., & Wang, Q. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04690-3 · Cited by 10
Ogbomo, A. S., Tsang, Y., Kariburyo, F., Tsai, W.-L., & Panjabi, S. S. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00173-6 · Cited by 10
Howard, L. (2018) · European Respiratory Journal · doi:10.1183/13993003.00996-2018 · Cited by 10
Ţilea, I., Iancu, D.-G., Firă-Mladinescu, O., Bertici, N. S., & Varga, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020767 · Cited by 9
“These changes impose an increasing haemodynamic load on the right ventricle (RV), ultimately leading to RV failure—the principal determinant of morbidity and mortality in PAH [1,2].”
InfluentialSweatt, A. J., Reddy, R. M., Rahaghi, F. N., Al‐Naamani, N., & American Thoracic Society Pulmonary Circulation Assembly Early Career Working Group (2021) · Pulmonary Circulation · doi:10.1177/20458940211040713 · Cited by 9
Avitabile, C. M., McBride, M. G., Harris, M. A., Whitehead, K. K., Fogel, M. A., Paridon, S. M., & Zemel, B. S. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1025420 · Cited by 9
Hu, X., Ding, N., Songchen, W., Wang, R., Chen, J., Zhong, A., Nan, J., Zuo, Y., Huang, H., & Tian, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080350 · Cited by 9
“The original REVEAL risk calculator was an algorithm that used 12 baseline parameters to calculate the risk score, predicting 12-month survival and providing useful serial survival assessments for patients with PAH [19,22,23].”
MethodBorhani, A., Porter, K. K., Umair, M., Chu, L. C. H., Mathai, S. C., Kolb, T. M., Damico, R. L., Hassoun, P. M., Kamel, I. R., & Zimmerman, S. L. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12298 · Cited by 9
“15 32 Since, we showed that circulation ( ᴦ ) is related to the PA diameter and mean PA pressure, we believe this metric can be employed for risk stratification in PAH patients.”
MethodToma, M., Savonitto, G., Lombardi, C. M., Airò, E., Driussi, M., Gentile, P., Howard, L., Moschella, M., Poi, E. D., Pagnesi, M., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02448-9 · Cited by 9
“The mean score rounded to the next integer defined the patient global risk as low, intermediate, or high [11, 19].”
InfluentialZhang, S., Gao, L., Li, S., Luo, M., Xi, Q., Lin, P., Zhao, Z., Zhao, Q., Yang, T., Zeng, Q., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02476-9 · Cited by 9
“Patients were classified into low-, intermediate-, or high-risk categories based on the abbreviated ESC 3-strata risk stratification strategy [28].”
BackgroundBerlier, C., Schwarz, E. I., Saxer, S., Lichtblau, M., & Ulrich, S. (2019) · Lung · doi:10.1007/s00408-019-00222-7 · Cited by 9
Novel molecular insights and public omics data in pulmonary hypertension
López‐Crisosto, C., Arias‐Carrasco, R., Sepúlveda, P., Garrido‐Olivares, L., Maracaja‐Coutinho, V., Verdejo, H., Castro, P., & Lavandero, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166200 · Cited by 9
Rezende, C. F., Mancuzo, E. V., & Corrêa, R. D. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268839 · Cited by 9
“Clinical and laboratory assessments, N-terminal pro-brain-type natriuretic peptide (NT-proBNP), echocardiography, right heart catheterization (RHC) variables and the Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) risk score were recorded before the initiation of PAH therapy [1,…”
MethodRemiszewski, P., Pędzińska‐Betiuk, A., Mińczuk, K., Schlicker, E., Klimek, J., Dzięcioł, J. B., & Malinowska, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.965613 · Cited by 9
“, 2021), PAH is considered a significant issue due to its high mortality (5years survival rate from 68% in patients with low risk to 23% in the high-risk group) (Hoeper et al., 2017).”
BackgroundRemiszewski, P., & Malinowska, B. (2022) · Pharmaceuticals · doi:10.3390/ph15091119 · Cited by 9
Fadah, K., Rodriguez, J. B. C., Alkhateeb, H., Mukherjee, D., García, H., Schuller, D., Mohammad, K. O., Sahay, S., & Nickel, N. P. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12209 · Cited by 9
Kramer, T., Nattmann, P., Gerhardt, F., Stafiej, P., Dumitrescu, D., ten Freyhaus, H., Wißmüller, M., Hohmann, C., Baldus, S. E., & Rosenkranz, S. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14611 · Cited by 9
“The mean grade was rounded off to the nearest integer, which was used to de fi ne the patient ’ s risk group 15,16 ; (ii) Overall risk assessment by the 4-strata approach, according to cut-off values for WHO-FC, 6MWD, and NTproBNP de fi ned in the ESC/ERS guidelines.”
MethodSelf-citationDemerouti, E., Karyofyllis, P., Manginas, A., Anthi, A., Karatasakis, G., Athanassopoulos, G. D., & Voudris, V. V. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00319-z · Cited by 9
Pulmonary arterial hypertension in the emergency department: A focus on medication management
Barlow, A., Barlow, B., Koyfman, A., Long, B., & Bissell, B. D. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.03.072 · Cited by 9
Grignola, J. C., Domingo, E., López‐Meseguer, M., Trujillo, P., Bravo, C., Pérez‐Hoyos, S., & Román, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.631326 · Cited by 9
“Our findings strengthen the inappropriateness of the term “stable,” even for patients in the low-risk category who may have a significant PA remodeling with a RV-PA coupling reserve exhausted (Boucly et al., 2017; Hoeper et al., 2017; Kylhammar et al., 2018), and also supports not only low-risk profile as a pursue tre…”
BackgroundMethodRisk Assessment and Survival of Pulmonary Hypertension Patients: Multicenter Experience in Turkey
Yaylalı, Y. T., Başarıcı, I., Avcı, B. K., Meriç, M., Sinan, Ü. Y., Şenol, H., Küçükoğlu, M. S., & Öngen, Z. (2019) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2019.53498 · Cited by 9
“(4) reported that an abbreviated version of the risk assessment strategy proposed by the guidelines provides accurate mortality estimates in patients with PAH.”
BackgroundResultHumbert, M. J. C., & Lau, E. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.07.005 · Cited by 9
Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
Stubbe, B., Seyfarth, H., Kleymann, J., Halank, M., Ghorani, H. A., Obst, A., Desole, S., Ewert, R., & Opitz, C. F. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01499-2 · Cited by 9
Self-citationPrecision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series)
Forbes, L. M., Bauer, N. N., Bhadra, A., Bogaard, H. J., Choudhary, G., Goss, K. N., Gräf, S., Heresi, G. A., Hopper, R. K., Jose, A., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70027 · Cited by 8
Refining Risk Prediction in Systemic Sclerosis–Associated Pulmonary Arterial Hypertension
Osgueritchian, R., Jani, V., Mombeini, H., Gami, A., Goldin, G., Hsu, S., Hummers, L. K., Wigley, F. M., Lammi, M. R., Ambale‐Venkatesh, B., et al. (2025) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2025.07.013 · Cited by 8
Diesler, R., Turquier, S., Reynaud‐Gaubert, M., Lestelle, F., Lacoste-Palasset, T., Valentin, V., Quétant, S., Chaouat, A., Boissin, C., Noël‐Savina, E., et al. (2026) · European Respiratory Journal · doi:10.1183/13993003.02233-2025 · Cited by 8
Shi, Y., Dong, X., Hu, X., Weng, L., Liu, Y., Lai, J., Tian, Z., Zhao, J., Li, M., Peng, J., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02056-1 · Cited by 8
Leong, K., Howard, L., Giudice, F. L., Davies, R. J., Haji, G., Gibbs, S., & Gopalan, D. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12116 · Cited by 8
Díez, M., Cáneva, J., Diez, A., Perna, E. R., Aimone, D., Bosio, M., Márquez, L. L. L., Brasca, D. G., Vulcano, N. O., Daghero, F., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100945 · Cited by 8
Omura, J., Kitahara, K., Takano, M., Idehara, K., & Kim, S. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12275 · Cited by 8
“Although PAH‐related symptoms are common, given the rarity of this fatal disease, patient registries are fundamental to understanding demographic characteristics, the natural history of the disease, risk factors, progression, and treatment response.(6,7) However, given their intrinsic design, such registry studies are…”
BackgroundPhenotype and Outcomes According to Loop Diuretic Use in Pulmonary Arterial Hypertension
Savonitto, G., Barbisan, D., Ameri, P., Lombardi, C. M., Monti, S., Driussi, M., Gentile, P., Howard, L., Toma, M., Pagnesi, M., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14818 · Cited by 8
Bereczky, Z., Kolodzey, G., Borsos, S., Balogh, L., Biró, P. E., Molnar, E. M., Rázsó, K., Péter, A., Barta, J., & Szük, T. (2025) · Genes · doi:10.3390/genes16111336 · Cited by 8
“This progressive disorder, which occurs in approximately 2–4% of PE survivors, is associated with increased pulmonary vascular resistance, right ventricular dysfunction, and ultimately right heart failure if left untreated [5–8].”
Göransson, C., Vejlstrup, N. G., Scheike, T., & Carlsen, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.11.020 · Cited by 8
Zhao, J., Wang, Q., Wang, Q., Zhang, Y., Zhang, N., Zhang, R., Hao, Y., Jia, J., Li, M., & Zeng, X. (2021) · Rheumatology and Immunology Research · doi:10.2478/rir-2021-0010 · Cited by 8
Moceri, P., Duchateau, N., Baudouy, D., Squara, F., Bun, S. S., Ferrari, É., & Maxime Sermesant, B. (2021) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeab240 · Cited by 8
Körbelin, J., Klein, J., Matuszcak, C., Runge, J., Harbaum, L., Klose, H. F. E., & Hennigs, J. K. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1036096 · Cited by 8
Characteristics of Japanese elderly patients with pulmonary arterial hypertension
Takahashi, Y., Yamamoto, K., Tanabe, N., Suda, R., Koshikawa, K., Ikubo, Y., Suzuki, E., Shoji, H., Naito, A., Kasai, H., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019873546 · Cited by 8
Liu, B., Wu, W., Zeng, Q., Liu, Z., Niu, L., Tian, Y., Luo, Q., Zhao, Z., Quan, R., Lin, J., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019894525 · Cited by 8
“Risk assessment was performed in accordance with 2015 ESC Guidelines(4) and other two previous reports.(13,14) Patients were classified into low-, intermediate-, and highrisk groups in terms of WHO-FC, NT-proBNP, exercise capacity (6MWD or PVO2), and hemodynamic parameters detected by RHC (RAP, Ci, and SvO2), which is…”
MethodTaran, I. N., Андреевна, Б. А., Солтановна, В. З., Saidova, M. A., & Martynyuk, T. V. (2020) · PULMONOLOGIYA · doi:10.18093/0869-0189-2020-30-4-427-436 · Cited by 8
Inhaled iloprost as third add‐on therapy in idiopathic pulmonary arterial hypertension
Fernandes, C. J. C. D. S., da Silva, T. A. F., Alves, J. L., Jardim, C., & Souza, R. (2020) · Pulmonary Circulation · doi:10.1177/2045894020981350 · Cited by 8
“Use of double combination therapy (an ERA plus a PDE5i) without achieving low-risk status in European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines risk stratification, evaluated as previously suggested.(14) 3.”
MethodHayashi, R., Kogiso, T., Kikuchi, N., Yamamoto, K., Nakamura, S., Egawa, H., Hagiwara, N., & Tokushige, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267125 · Cited by 8
“Advanced treatments for PAH have significantly improved survival [10, 22, 23].”
BackgroundComments on the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension
SEC Working Group for the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension and SEC Guidelines Committe (2022) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2022.11.001 · Cited by 8
Bluro, I. M., Barbagelata, L., Coronel, M. L., Melatini, L., Svetliza, G., Vulcano, N., Atamañuk, A. N., Masson, W. M., & Pizarro, R. (2023) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v91.i2.20613 · Cited by 8
Management of Pulmonary Arterial Hypertension
Weatherald, J. C., Varughese, R. A., Liu, J., & Humbert, M. J. C. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1770118 · Cited by 8
da Silva, M. D. M. C., Alencar, A. K. N., da Silva, J. S., Montagnoli, T. L., da Silva, G. F., Rocha, B., Montes, G. C., Méndez‐Otero, R., Pimentel‐Coelho, P. M., Vasques, J. F., et al. (2020) · Cells · doi:10.3390/cells9092120 · Cited by 8
“Mortality consequent to PAH is high [12] because current therapy fails to reverse the structural and signaling changes in pulmonary arteries (deregulated angiogenesis, high production and release of growth factors, strong resistance to apoptosis, abnormal formation of an inflammatory environment within and surrounding…”
BackgroundPalliative Care and Advance Care Planning in Pulmonary Hypertension
Rhee, C. L., & Cuttica, M. J. (2018) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-17.1.15 · Cited by 8
“Within the last several years the PH community is getting much better at identifying these “high-risk” patients in whom survival is limited despite best available therapy.(10,11,13) It is this population that would most benefit from early engagement with palliative care and the concepts introduced in this manuscript.”
BackgroundAlotaibi, M., Harvey, L. D., Nichols, W. C., Pauciulo, M. W., Hemnes, A. R., Long, T., Watrous, J. D., Begzati, A., Tuomilehto, J. O., Havulinna, A. S., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag383 · Cited by 8
Мерабович, Ш. А., & Martynyuk, T. V. (2021) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20211603123 · Cited by 7
Advances in the discovery of drugs that treat pulmonary arterial hypertension
Zolty, R. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2192919 · Cited by 7
“Also, the European COMPERA with 1588 PAH subjects [102] and the Swedish SPAHR [103] registries, which used six”
MethodAssessing quality of life in pulmonary arterial hypertension: An independent prognostic marker
Reeves, G. E. M., Shepherd, J., Collins, N. J., Twaddell, S. H., & Singh, R. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12380 · Cited by 7
Abouzaid, A., Ali, K., Jatoi, S., Ahmed, M., Ahmad, G., Nazim, A., Mehmoodi, A., & Malik, J. (2024) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.70010 · Cited by 7
Oba, Y., Maduke, T., Fakhouri, E. W., & Goite, Y. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015824.pub2 · Cited by 7
Treating pulmonary hypertension in the elderly
Campean, I., & Lang, I. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1739270 · Cited by 7
“Data from international PH registries indicate that despite more severe disease at this age the concept of hit hard and early is less used in the elderly population, purporting worse outcomes [8,20,22,44].”
BackgroundRadchenko, G., & Sirenko, Y. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s294767 · Cited by 7
Kaymaz, C., Tanyeri, S., Tokgöz, H. C., Akbal, Ö. Y., Karagöz, A., Keskin, B., Kültürsay, B., Hakgör, A., Külahçıoğlu, Ş., Bayram, Z., et al. (2022) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2022.1889 · Cited by 7
Wang, M.-T., Chi, P., Cheng, C.-C., Huang, W., & Chen, L.-W. (2023) · Cardiology Journal · doi:10.5603/cj.92813 · Cited by 7
Lawrie, A., Hamilton, N., Wood, S., Exposto, F., Muzwidzwa, R., Raiteri, L., Beaudet, A., Muller, A., Sauter, R., Pillai, N., et al. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12399 · Cited by 7
Mularek‐Kubzdela, T., Ciurzyński, M., Kowal‐Bielecka, O., Kasprzak, J. D., Kopeć, G., Mizia‐Stec, K., Mroczek, E., Lewicka, E., Skoczylas, I., Grabka, M., et al. (2021) · Kardiologia Polska · doi:10.33963/kp.a2021.0055 · Cited by 7
“Several risk stratification tools exist, including the REVEAL 2 scale [39], risk assessment based on the Swedish [40], French [41], COMPERA [42] registry, and ESC risk tables [31].”
MethodUpdate on Medical Management of Pulmonary Arterial Hypertension
Sherman, A. E., Saggar, R., & Channick, R. N. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.002 · Cited by 7
Steenhorst, J. J., Hirsch, A., Verzijl, A., Wielopolski, P. A., de Wijs-Meijler, D. P. M., Duncker, D. J., Reiss, I. K. M., & Merkus, D. (2022) · The Journal of Physiology · doi:10.1113/jp282906 · Cited by 7
“Secondary hits could induce further worsening of PVD and may even result in PAH with its devastating course of disease progression (Goss et al., 2017; Hoeper et al., 2017; McLaughlin & Suissa, 2010).”
BackgroundPulmonary Hypertension in Scleroderma– Evaluation and Management
Chennakesavulu, P. V., Uppaluri, S., Koyi, J., Jhaveri, S., Avanthika, C., Sakhamuri, L. T., Ashokbhai, P. K., & Singh, P. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101468 · Cited by 7
Bartenstein, P., Saxer, S., Appenzeller, P., Lichtblau, M., Schwarz, E. I., & Ulrich, S. (2018) · Respiration · doi:10.1159/000488000 · Cited by 7
Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
Gong, S., Wu, W., Li, C., Zhao, Q., Jiang, R., Luo, C., Qiu, H., Liu, J., Wang, L., & Zhang, R. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.745578 · Cited by 7
“Median interval between diagnosis and re-evaluation was 13 [5, 33] months.”
BackgroundMethodInfluentialVraka, A., Yerly, P., & Aubert, J. (2022) · Respiration · doi:10.1159/000520886 · Cited by 7
Diez años de experiencia de un centro de referencia en hipertensión arterial pulmonar en Uruguay
Gruss, A., Pascal, G., Chao, C., Janssen, B., Bedó, C., Salisbury, J. P., Trujillo, P., Curbelo, P., & Grignola, J. C. (2019) · Revista Médica del Uruguay · doi:10.29193/rmu.35.3.3 · Cited by 7
“Se estimó el riesgo global en el momento del diagnóstico mediante un modelo de cuatro variables (CF de la Organización Mundial de la Salud, DR6M, PAD, IC)(13).”
BackgroundInfluentialPulmonary arterial hypertension: assessing risk to improve prognosis
Kjellström, B., Hjalmarsson, C., Kylhammar, D., & Rådegran, G. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1548278 · Cited by 7
“Such a strategy for risk assessment was recently evaluated in three large registry PAH-populations, the Swedish PAH registry SPAHR [3], the French PH registry [4], and the multinational European PH registry COMPERA [5].”
BackgroundThe importance of right ventricular remodelling in pulmonary arterial hypertension
D’Alto, M., & Badagliacca, R. (2022) · Heart · doi:10.1136/heartjnl-2022-321143 · Cited by 7
Hsieh, Y. J., Ho, W., Lin, C., Luo, S., Yu, K., Chen, J.-Y., Hsiao, F., & Chang, C.-Y. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20221104a · Cited by 6
Morland, K., Gerges, C., Elwing, J., Visovatti, S., Weatherald, J. C., Gillmeyer, K. R., Sahay, S., Mathai, S. C., Boucly, A., Williams, P., et al. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12317 · Cited by 6
Castillo‐Galán, S., Parra, V., & Cuenca, J. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167519 · Cited by 6
Metadata
- Authors
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., Distler, O., Opitz, C., Gibbs, J. S. R., Delcroix, M., Ghofrani, H. A., Huscher, D., Pittrow, D., Rosenkranz, S., & Grünig, E.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Cologne (DE)
- University Hospital Heidelberg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Sapienza University of Rome (IT)
- University Hospital Zurich (CH)
- DRK Kliniken Berlin (DE)
- Imperial College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Justus-Liebig-Universität Gießen (DE)
- Technische Universität Dresden (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700740
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2743897368
- Cited by
- 660
- References
- 21
- Citations by year
- 2026: 21 · 2025: 52 · 2024: 74 · 2023: 84 · 2022: 101 · 2021: 111 · 2020: 92 · 2019: 63 · 2018: 53 · 2017: 8
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- GlaxoSmithKline
- German Centre of Lung Research
- Bayer
- Actelion Pharmaceuticals
- Deutsche Forschungsgemeinschaft (HO 1599/2-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, mortality prediction, risk stratification, one-year mortality, functional class, 6-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, mixed venous oxygen saturation
- MeSH terms
- Walk Test, Adult, Aged, Aged, 80 and over, Europe, Female, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prospective Studies, Registries, Severity of Illness Index, Practice Guidelines as Topic, Risk Assessment, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.